Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future
Version of Record online: 26 OCT 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Reviews in Medical Virology
Volume 18, Issue 1, pages 19–34, January/February 2008
How to Cite
Férir, G., Kaptein, S., Neyts, J. and De Clercq, E. (2008), Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev. Med. Virol., 18: 19–34. doi: 10.1002/rmv.554
- Issue online: 21 DEC 2007
- Version of Record online: 26 OCT 2007
- Manuscript Accepted: 16 JUL 2007
- Manuscript Revised: 12 JUL 2007
- Manuscript Received: 11 APR 2006
- Priority 1 ‘Life Sciences, Genomics and Biotechnology for Health’. Grant Number: LSHM-CT-2004-503359
- FWO. Grant Number: G.0267.04
- KULeuven. Grant Number: GOA 2005/19
A decade ago, standard therapy against chronic hepatitis B virus infections only consisted of lamivudine or IFN-α. Treatment with lamivudine and IFN has been compounded by, respectively, the emergence of drug-resistant virus strains and the appearance of serious side effects. In the last 10 years, hepatitis B treatment has made much progress. Several treatments are now licensed for the treatment of patients with chronic hepatitis B and others are under development. Here, we provide an overview of the potential and mode of action of anti-HBV agents that are currently available, and/or may become available in the near future. Foremost among these newer compounds are adefovir dipivoxil, entecavir and telbivudine. Copyright © 2007 John Wiley & Sons, Ltd.